SAMe tablets provided by Douglas Laboratories®
deliver 200 mg of S-adenosyl-methionine in an
enteric-coated form for added stability.
Supplied in bottles of 30 tablets.
Each Enteric-coated tablet contains:
- S-Adenosyl-methionine 200 mg (S-Adenosl-methionine disulfate tosylate)
Suggested Dose: Adults take 1 tablet daily or as directed by physician
Store in cool dry area at room temperature.
Enteric Coated SAM-e does not require refigeration though it can be refrigerated
to extend its shelf-life.
Read Customer questions and answers about Mental Health in our FAQ.
SAMe (S-adenosyl-methionine) has been shown to be efficacious in several health disorders. Although SAMe, as a methyl donor, participates in a wide variety of biochemical reactions, there are several specific health problems, i.e. osteoarthritis, depression, cognitive dysfunction, liver disease, and gall bladder disease, that appear to be benefited by its administration.
SAMe’s antiarthritic action depends not only on its reduction of inflammation and associated pain, but also on its putative participation in proteoglycan synthesis and joint cartilage repair. SAMe is thought to function physiologically as a signal of sulfur availability. Some suggest that supplemental SAMe may compensate for the decreased SAMe levels in chondrocytes induced by the inflammatory cytokine interleukin-1, and thus upregulate the chondrocyte’s synthesis of joint proteoglycans.
As a major source of methyl groups in the brain, SAMe, in conjunction with other methyl donor metabolites such as betaine, choline, or folate, may optimize the synthetic/degradative rate of neurotransmitters, i.e. serotonin and dopamine, and the brain’s sensitivity to them. With few side effects SAMe has been shown in meta analysis of multiple studies to offer tangible benefits to depressed individuals. These effects are comparable to those afforded by standard tricyclic antidepressants.
As a hepatoprotective compound, SAMe has been shown to prevent the adverse biochemical alterations induced by lead and/or alcohol exposure. This characteristic of SAMe’s activity is also effective in protecting the central nervous system. SAMe has also been shown to protect the liver against drug and viral assaults. SAMe can be an integral part of a hepatoprotective therapeutic regimen. Other studies have indicated that SAMe may decrease cholestasis. By optimizing a healthy flow of bile, the risk of gall stones may be reduced with SAMe supplementation.
SAMe tablets may be a useful nutritional supplement for individuals looking for its neurological as well as joint-related benefits.
References:
- Bottiglieri, T, Hyland, K, Reynolds, EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994;48:137-52.
- Bressa, GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 1994;154:7-14.
- Domljan, Z, Vrhovac, B, Durrigl, T, Pucar, I. A double-blind trial of ademetionine vs naproxen in activated gonarthrosis. Int J Clin Pharmacol Ther Toxicol 1989;27:329-33.
- Flora, GJ, Seth, PK. Beneficial effects of S-adenosyl-L-methionine on aminolevulinic acid dehydratase, glutathione, and lipid peroxidation during acute lead- ethanol administration in mice. Alcohol 1999;18:103-8.
- Goodnick, PJ, Sandoval, R. Psychotropic treatment of chronic fatigue syndrome and related disorders. J Clin Psychiatry 1993;54:13-20.
- Gorbakov, VV, Galik, VP, Kirillov, SM. [Experience in heptral treatment of diffuse liver diseases]. Ter Arkh 1998;70:82-6. Mato, JM, Camara, J, Fernandez de Paz, J, Caballeria, L, Coll, S, Caballero, A, Garcia-Buey, L, Beltran, J, Benita, V, Caballeria, J, Sola, R, Moreno-Otero, R, Barrao, F, Martin-Duce, A, Correa, JA, Pares, A, Barrao, E, Garcia-Magaz, I, Puerta, JL, Moreno, J, Boissard, G, Ortiz, P, Rodes, J. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999;30:1081-9.
- McCarty, MF, Russell, AL. Niacinamide therapy for osteoarthritis-- does it inhibit nitric oxide synthase induction by interleukin 1 in chondrocytes? Med Hypotheses 1999;53:350-60.
- Osman, E, Owen, JS, Burroughs, AK. Review article: S-adenosyl- L-methionine--a new therapeutic agent in liver disease? Aliment Pharmacol Ther 1993;7:21-8.
- Salmaggi, P, Bressa, GM, Nicchia, G, Coniglio, M, La Greca, P, Le Grazie, C. Double-blind, placebo-controlled study of S-adenosyl-Lmethionine in depressed postmenopausal women. Psychother Psychosom 1993;59:34-40.
|
|